RARE · CIK 0001515673 · FY2025 live · 2025-12-31
Ultragenyx Pharmaceutical Inc.
View as
Model
Classic Z
FY2025
−4.44
Zone
Distress
Prior
—
Market DD
—
1y PD
—
−4.44
Z″ −9.61
Score −4.44 · distress below 1.80, grey to 2.99, safe at 3.00 and above.
Classic Z factor contributions
X1 Working capital / assets
Short-term liquidity versus the size of the balance sheet.
0.371.2 × = 0.44X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
−2.961.4 × = −4.14X3 EBIT / assets
Operating return on assets. Highest weight in the original model.
−0.353.3 × = −1.15X4 Book equity / liabilities
Book equity versus the liability stack. Mega-caps often look greyer here than they would if X4 used market cap.
−0.050.6 × = −0.03X5 Sales / assets
Asset turnover — how much revenue the asset base supports.
0.441 × = 0.44
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings rather than invent a series.
Overview
rule-v1
Ultragenyx Pharmaceutical Inc. is on classic Z at −4.44 (distress) for FY2025, from an SEC 10-K. Retained earnings / assets is the line that sets the print. This is the first live year on the desk. No market tape loaded. Classic Z was fit on manufacturers; buybacks can send retained earnings negative at otherwise healthy issuers, and X4 is book equity, not market cap.
Book screen Distress; market PD —. Tape not priced — not a single default call.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Classic Z scores · 32nd percentile in Healthcare.
- AQSTDistressAquestive Therapeutics, Inc.−4.43
- RLMDDistressRELMADA THERAPEUTICS, INC.−4.43
- ANNXDistressAnnexon, Inc.−4.41
- TILDistressInstil Bio, Inc.−4.41
- IRWDDistressIRONWOOD PHARMACEUTICALS INC−4.48
- MENSDistressJyong Biotech Ltd.−4.40
- CYTKDistressCYTOKINETICS INC−4.37
- SNDXDistressSyndax Pharmaceuticals Inc−4.35
KPI widgets
Current assets
$951M
Total assets
$1.5B
Current liabilities
$384M
Total liabilities
$1.6B
Working capital
$567M
Retained earnings
−$4.5B
EBIT
−$535M
Total sales
$673M
Book equity
−$80M
Accession 0001193125-26-057329. Live rank is the latest 10-K on EDGAR (FY2025, period 2025-12-31). Classic Z is the live score. View as does not rewrite the live rank. X4 is book equity. Pulled 12 Sept 2026.